Quantitative analysis of ezetimibe in human plasma by gas chromatography-mass spectrometry

Development of core-shell magnetic molecularly imprinted polymer-based electrochemical sensor for sensitive and selective detection of ezetimibe

A sensitive electrochemical molecularly imprinted polymer (MIP) sensor was fabricated for detection of ezetimibe (Eze) as an effective cholesterol absorption inhibitor on the surface of a screen-printed carbon electrode based on a magnetic nanoparticle decorated with MIP (Fe₃O₄@MIP). Placing the magnetic nanoparticle inside the MIP increases the biocompatibility, surface-to-volume ratio, and sensitivity of the sensor. Methacrylic acid (MAA) was used as a monomer, ethylene glycol dimethacrylate (EGDMA) as a cross-linker, and Eze as a template. The fabricated Fe₃O₄@MIP was characterized using Fourier-transform infrared spectroscopy (FTIR), Transmission electron microscopy (TEM), and scanning electron microscopy (SEM). Detection of Eze was achieved by differential pulse voltammetry. Using this sensor, Eze can be sensitively detected in the range of 1.0 nM-10 μM and detection limit of 0.7 nM. In addition, we have shown that the proposed sensor successfully detects different concentrations of Eze in human serum samples and thus proves its practical application.

Establishment and application of quantitative method for 22 organic acids in honey based on SPE-GC–MS

Honey, a natural healthy liquid bee product, is rich in amino acids, vitamins, and other essential nutrients. Different origin honeys also varied in organic acids. The objective of this study is to establish an efficient solid-phase extraction-gas chromatography–mass spectrometry (SPE-GC–MS) method to eliminate interference of sugar and other impurities for accurately estimating 22 organic acids in honey by optimizing extraction, purification, derivatization, and gas chromatography–mass spectrometry (GC–MS) analytical conditions. After being extracted, purified and derivatized, organic acids in honey were qualified and quantified by GC–MS. This method was evaluated experimentally, and the results showed that, within a certain concentration range, the standard curve linear relationship was satisfactory (R2 > 0.9942), and the target organic acid recovery rate was 86.74% ~ 118.68%. Besides, precision (relative standard deviation, RSD = 2.98% ~ 13.42%), detection limit (LOD = 0.002 ~ 0.2 mg kg−1), and quantification limit (LOQ = 0.008 ~ 0.5 mg kg−1) met the target requirements. Also, based on this analytical method, the organic acids in five types of honey (acacia, jujube, vitex, canola and linden honey) were estimated. Notably, they all contained 22 different kinds of organic acids, and significant differences (p < 0.05) in the organic acid content and composition among different honey varieties were observed. PCA analysis showed that the five honeys could be differentiated based on the content of 22 organic acids.

Ezetimibe: A Review of Analytical Methods for the Drug Substance, Pharmaceutical Formulations and Biological Matrices

Ezetimibe (EZM) is a selective inhibitor of the sterol transporter Niemann-Pick C1-Like 1 in the small intestine used as an adjunctive therapy to lower cholesterol levels in cases of hyperlipidemia. The goal of this work was to summarize the main physical-chemical, pharmacological and pharmacokinetic characteristics of EZM, as well as to describe the main analytical methodologies for the quantification of the drug. Methods described in the United States Pharmacopeia for EZM raw material and tablets were also presented. The drug has a large number of process-related impurities and degradation products and needs strict quality control of its impurities. Specific chiral methods for the evaluation of its chiral impurities are also a need for EZM. The main advantages and disadvantages of the compiled analytical methods were presented, as well as the limits of detection and quantitation. The fastest and most efficient methods were highlighted. Most methods for analyzing EZM used C₈ or C₁₈ stationary phases in gradient mode with binary mobile phases containing acetonitrile and an acidic buffer solution with ultraviolet detection. For analysis of EZM in biological matrices, liquid chromatography-tandem mass spectrometry is generally employed using electron spray ionization in negative ionization mode using multiple reaction monitoring. Different methods in the literature evaluate a large number of impurities for EZM, however new stability-indicating high-performance liquid chromatography methods for the drug are still needed.

Microemulsion liquid chromatographic method for simultaneous determination of simvastatin and ezetimibe in their combined dosage forms

A rapid HPLC procedure using a microemulsion as an eluent was developed and validated for analytical quality control of antihyperlipidemic mixture containing simvastatin (SIM) and ezetimibe (EZT) in their pharmaceutical preparations. The separation was performed on a column packed with cyano bonded stationary phase adopting UV detection at 238 nm using a flow rate of 1 mL/min. The optimized microemulsion mobile phase consisted of 0.2 M sodium dodecyl sulphate, 1% octanol, 10% n-propanol, and 0.3% triethylamine in 0.02 M phosphoric acid at pH 5.0. The developed method was validated in terms of specificity, linearity, lower limit of quantification (LOQ), lower limit of detection (LOD), precision, and accuracy. The proposed method is rapid (8.5 min), reproducible (RSD < 2.0%) and achieves satisfactory resolution between SIM and EZT (resolution factor = 2.57). The mean recoveries of the analytes in pharmaceutical preparations were in agreement with those obtained from a reference method, as revealed by statistical analysis of the obtained results using Student's t-test and the variance ratio F-test.

Simultaneous determination of ezetimibe and simvastatin in rat plasma by stable-isotope dilution LC-ESI-MS/MS and its application to a pharmacokinetic study

A simple, sensitive and specific liquid chromatography–tandem mass spectrometry method was developed for simultaneous quantification of ezetimibe and simvastatin in rat plasma. The deuterium isotopes: ezetimibe d₄ and simvastatin d₆ were used as internal standards for ezetimibe and simvastatin, respectively. MS/MS detection involved a switch of electron spray ionization mode from negative to positive at retention time 3.01 min. Samples were extracted from plasma by liquid–liquid extraction using tertiary butyl methyl ether. Chromatographic separation was achieved with Agilent Eclipse XBD-C₁₈ column using mobile phase that consisted of a mixture of ammonium acetate (pH4.5; 10 mM)–acetonitrile (25:75 v/v). The method was linear and validated over the concentration range of 0.2–40.0 ng/mL for simvastatin and 0.05–15.0 ng/mL for ezetimibe. The transitions selected were m/z 408.3→271.1 and m/z 412.0→275.10 for ezetimibe and ezetimibe d₄, and m/z 419.30→285.20 and m/z 425.40→199.20 for simvastatin and simvastatin d₆. Intra- and inter-batch precisions for ezetimibe were 1.6–14.8% and 2.1–13.4%; and for simvastatin 0.94–9.56% and 0.79–12%, respectively. The proposed method was sensitive, selective, precise and accurate for the quantification of ezetimibe and simvastatin simultaneously in rat plasma. The method was successfully applied to a pharmacokinetic study by oral co-administration of ezetimibe and simvastatin in SD rats.

Two spectrophotometric methods for simultaneous determination of some antihyperlipidemic drugs

Two simple, accurate, precise and economic spectrophotometric methods have been developed for simultaneous determination of Atorvastatin calcium (ATR) and Ezetimibe (EZ) in their bulk powder and pharmaceutical dosage form. Method (I) is based on dual wavelength analysis while method (II) is the mean centering of ratio spectra spectrophotometric (MCR) method. In method (I), two wavelengths were selected for each drug in such a way that the difference in absorbance was zero for the second drug. At wavelengths 226.6 and 244 nm EZ had equal absorbance values; therefore, these two wavelengths have been used to determine ATR; on a similar basis 228.6 and 262.8 nm were selected to determine EZ in their binary mixtures. In method II, the absorption spectra of both ATR and EZ with different concentrations were recorded over the range 200-350, divided by the spectrum of suitable divisor of both ATR and EZ and then the obtained ratio spectra were mean centered. The concentrations of active components were then determined from the calibration graphs obtained by measuring the amplitudes at 215-260 nm (peak to peak) for both ATR and EZ. Accuracy and precision of the developed methods have been tested; in addition recovery studies have been carried out in order to confirm their accuracy. On the other hand, selectivities of the methods were tested by application for determination of different synthetic mixtures containing different ratios of the studied drugs. The developed methods have been successfully used for determination of ATR and EZ in their combined dosage form and statistical comparison of the developed methods with the reported spectrophotometric one using F and Student's t-tests showed no significant difference regarding both accuracy and precision.

Ezetimibe

Ezetimibe is a drug substance which can be used for lowering low-density lipoprotein cholesterol. Its crystal form and polymorphism have been determined using X-ray diffraction and thermal methods. Quantitative and qualitative analysis of Ezetimibe as well as study of its impurities and degradations were summarized in this chapter.

Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR

A major process-related impurity associated with the synthesis of ezetimibe was detected by LC-MS. The isolated impurity was found not to have been previously reported. Based on LC/MS/MS studies and accurate mass data, the structure of that impurity was proposed to be 2-(4-hydroxybenzyl)-N,5-bis-(4-fluorophenyl)-5-hydroxypentanamide. The postulated structure was unambiguously confirmed with the help of the NMR and IR analyses of a synthetically obtained sample. The chemical shift of the labile proton of that new entity was assigned by a 2D-NOESY NMR experiment. A rationalization for the formation of this impurity is provided.